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Abstract
The 5-HT3 receptor (nomenclature as agreed by the NC-IUPHAR Subcommittee on 5-Hydroxytryptamine
(serotonin) receptors [66]) is a ligand-gated ion channel of the Cys-loop family that includes the zinc-activated
channels, nicotinic acetylcholine, GABAA and strychnine-sensitive glycine receptors. The receptor exists as a
pentamer of 4TM subunits that form an intrinsic cation selective channel [5]. Five human 5-HT3 receptor
subunits have been cloned and homo-oligomeric assemblies of 5-HT3A and hetero-oligomeric assemblies of 5-
HT3A and 5-HT3B subunits have been characterised in detail. The 5-HT3C (HTR3C, Q8WXA8), 5-HT3D
(HTR3D, Q70Z44) and 5-HT3E (HTR3E, A5X5Y0) subunits [83, 122], like the 5-HT3B subunit, do not form
functional homomers, but are reported to assemble with the 5-HT3A subunit to influence its functional
expression rather than pharmacological profile [124, 63, 157]. 5-HT3A, -C, -D, and -E subunits also interact with
the chaperone RIC-3 which predominantly enhances the surface expression of homomeric 5-HT3A receptor
[157]. The co-expression of 5-HT3A and 5-HT3C-E subunits has been demonstrated in human colon [82]. A
recombinant hetero-oligomeric 5-HT3AB receptor has been reported to contain two copies of the 5-HT3A subunit
and three copies of the 5-HT3B subunit in the order B-B-A-B-A [7], but this is inconsistent with recent reports
which show at least one A-A interface [96, 150]. The 5-HT3B subunit imparts distinctive biophysical properties
upon hetero-oligomeric 5-HT3AB versus homo-oligomeric 5-HT3A recombinant receptors [32, 41, 56, 85, 139,
129, 79], influences the potency of channel blockers, but generally has only a modest effect upon the apparent
affinity of agonists, or the affinity of antagonists ([17], but see [41, 30, 35]) which may be explained by the
orthosteric binding site residing at an interface formed between 5-HT3A subunits [96, 150]. However, 5-HT3A
and 5-HT3AB receptors differ in their allosteric regulation by some general anaesthetic agents, small alcohols
and indoles [138, 135, 71]. The potential diversity of 5-HT3 receptors is increased by alternative splicing of the
genes HTR3A and E [64, 19, 124, 123, 120]. In addition, the use of tissue-specific promoters driving expression
from different transcriptional start sites has been reported for the HTR3A, HTR3B, HTR3D and HTR3E genes,
which could result in 5-HT3 subunits harbouring different N-termini [152, 79, 120]. To date, inclusion of the 5-
HT3A subunit appears imperative for 5-HT3 receptor function.
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